Cargando…

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients

There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an innovative approach that will generate renewed inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freed, Ian M., Kasi, Anup, Fateru, Oluwadamilola, Hu, Mengjia, Gonzalez, Phasin, Weatherington, Nyla, Pathak, Harsh, Hyter, Stephen, Sun, Weijing, Al-Rajabi, Raed, Baranda, Joaquina, Hupert, Mateusz L., Chalise, Prabhakar, Godwin, Andrew K., A. Witek, Malgorzata, Soper, Steven A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526802/ https://www.ncbi.nlm.nih.gov/pubmed/37759489 http://dx.doi.org/10.3390/cells12182266

Ejemplares similares

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
por: Kasi, Anup, et al.
Publicado: (2020)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020)

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2020)

Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
por: Hentzen, Stijn, et al.
Publicado: (2023)

Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review
por: Kasi, Anup, et al.
Publicado: (2020)

Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience
por: Al-Jumayli, Mohammed, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study
por: Saeed, Anwaar, et al.
Publicado: (2020)

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
por: Saeed, Anwaar, et al.
Publicado: (2023)

Microfluidic Device for On-Chip Immunophenotyping and Cytogenetic Analysis of Rare Biological Cells
por: M. Weerakoon-Ratnayake, Kumuditha, et al.
Publicado: (2020)

Microsatellite Instability with BRAF V600E Associated with Delayed Presentation but Poor Survival in Stage III Colorectal Cancer
por: Karki, Sophiya, et al.
Publicado: (2023)

Scaling the immune incline in PDAC
por: Rojas, Luis A., et al.
Publicado: (2021)

Transverse Space Charge Effect During Bunch Compression in PDAC1 and PDAC2 Compressor Ring
por: Franchetti, Giuliano
Publicado: (2000)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule
por: Witek, Małgorzata A., et al.
Publicado: (2017)

Autophagy is required for PDAC glutamine metabolism
por: Seo, Ju-Won, et al.
Publicado: (2016)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
por: Richardson, Gary Edward, et al.
Publicado: (2023)

Is obesity a risk factor in cancer patients with COVID-19?
por: Park, Robin, et al.
Publicado: (2021)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

The Microbiome in PDAC—Vantage Point for Future Therapies?
por: Pfisterer, Nina, et al.
Publicado: (2022)

Developing a genetic signature to predict drug response in ovarian cancer
por: Hyter, Stephen, et al.
Publicado: (2017)

Combatting PDAC with two tumor-targeting small RNAs
por: Kasinski, Andrea L.
Publicado: (2019)

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021)

Loss of FGFR4 promotes the malignant phenotype of PDAC
por: D’Agosto, Sabrina, et al.
Publicado: (2022)

Targeting KRAS in PDAC: A New Way to Cure It?
por: He, Qianyu, et al.
Publicado: (2022)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC
por: Alhothali, Marwa, et al.
Publicado: (2019)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer
por: Raghavan, Rama, et al.
Publicado: (2016)

Immune-related somatic mutation genes are enriched in PDACs with diabetes
por: Wang, Kaixuan, et al.
Publicado: (2019)

AHNAK2 is a potential prognostic biomarker in patients with PDAC
por: Lu, Di, et al.
Publicado: (2017)

Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors
por: Gerrard, Diana L., et al.
Publicado: (2019)

SMAD4 Y353C promotes the progression of PDAC
por: Wang, Zusen, et al.
Publicado: (2019)

Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma
por: Jaworek, Christian, et al.
Publicado: (2021)

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
por: Papadakos, Stavros P., et al.
Publicado: (2022)

An integrated study to decipher immunosuppressive cellular communication in the PDAC environment
por: AVŞAR, Gülben, et al.
Publicado: (2023)

Mutant SF3B1 promotes malignancy in PDAC
por: Simmler, Patrik, et al.
Publicado: (2023)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_255s9r3m4b2u7ub19c9m4c0q3a